Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amondys 45, Exondys 51, and Vyondys 53 in DMD Duplications
NCT04179409Phase 2Completed
- Sponsor
- Kevin Flanigan (Nationwide Children's Hospital)
- Start
- Feb 2020
- Primary completion
- Sep 2021
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of casimersen, eteplirsen, golodirsen in Duchenne muscular dystrophy (DMD), sponsored by Kevin Flanigan (Nationwide Children's Hospital). Started Feb 2020; status: completed.
02
Drugs
casimerseneteplirsengolodirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT04179409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04179409.